Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

AMY TIERSTEN

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1558362566
CMS profile
251700
Location
NEW YORK, NY

General Payments · PY2018–2024

$48,549.74

  • Reported across 94 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$5,372.29

13 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $4,795.00 3
Food and Beverage $577.29 10

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Acerta Pharma LLC $4,795.00 3
NOVARTIS PHARMACEUTICALS CORPORATION $263.14 4
JAZZ PHARMACEUTICALS INC. $191.83 1
Daiichi Sankyo Inc. $68.16 3
PFIZER INC. $31.39 1
Stemline Therapeutics Inc. $22.77 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $20,395.11 22
PY2019 $11,014.87 21
PY2020 $6,233.12 13
PY2021 $179.02 5
PY2022 $218.33 7
PY2023 $5,137.00 13
PY2024 $5,372.29 13

Payment records · PY2024 (13)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
AstraZeneca Pharmaceuticals LP $1,370.00 08/01/2024 Consulting Fee Undisputed 01/23/2026 1110531931 CMS
AstraZeneca Pharmaceuticals LP $2,055.00 10/17/2024 Consulting Fee Undisputed 01/23/2026 1110531921 CMS
AstraZeneca Pharmaceuticals LP $1,370.00 12/23/2024 Consulting Fee Undisputed 01/23/2026 1110542549 CMS
Daiichi Sankyo Inc. $17.00 05/10/2024 Food and Beverage Undisputed 01/23/2026 1089491030 CMS
Daiichi Sankyo Inc. $25.96 07/17/2024 Food and Beverage Undisputed 01/23/2026 1089491032 CMS
Daiichi Sankyo Inc. $25.20 09/30/2024 Food and Beverage Undisputed 01/23/2026 1089491028 CMS
JAZZ PHARMACEUTICALS INC. $191.83 12/11/2024 Food and Beverage Undisputed 01/23/2026 1150220898 CMS
Novartis Pharmaceuticals Corporation $133.68 01/23/2024 Food and Beverage Undisputed 01/23/2026 1087345714 CMS
Novartis Pharmaceuticals Corporation $20.07 08/08/2024 Food and Beverage Undisputed 01/23/2026 1087345718 CMS
Novartis Pharmaceuticals Corporation $18.65 09/19/2024 Food and Beverage Undisputed 01/23/2026 1087345720 CMS
Novartis Pharmaceuticals Corporation $90.74 09/25/2024 Food and Beverage Undisputed 01/23/2026 1087345722 CMS
PFIZER INC. $31.39 04/16/2024 Food and Beverage Undisputed 01/23/2026 1131322442 CMS
Stemline Therapeutics Inc. $22.77 12/03/2024 Food and Beverage Undisputed 01/23/2026 1142957988 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.